The vaccine is being developed by the Anglo-Swedish laboratory AstraZeneca and is to be produced in Argentina and Mexico.
“We are shortening the process (…), but we expect to have results by the end of November (…) and start manufacturing to have the vaccine available in the first quarter of next year,” the leader told a news conference. the press.
Argentina and Mexico will manage the production and distribution in Latin America of the future coronavirus vaccine developed in collaboration with the AstraZeneca laboratory and Oxford University, with funding from the Carlos Slim Foundation. Brazil is not targeted because it has a separate agreement.
President López Obrador has assured that the vaccine will be “universal and free” in Mexico. “All Mexicans will have access to the vaccine. The neediest do not have to worry, “said the left-wing president.
“The idea is not to make a profit, but to guarantee access to Latin America,” Mexican Foreign Minister Marcelo Ebrard told a news conference.
Ebrard is to chair a virtual meeting of the Community of Latin American and Caribbean States (CELAC) to present the agreement on the vaccine and its distribution in the region, the body said on Twitter.
Argentine President Alberto Fernandez announced on Wednesday that Argentina and Mexico will produce and distribute in Latin America, with the exception of Brazil, the future vaccine against COVID-19 jointly developed by the AstraZeneca laboratory and Oxford University.
“AstraZeneca has signed an agreement with the Slim Foundation to produce between 150 and 200 million vaccines for all of Latin America, except Brazil, which will be available for the first half of 2021 and will be distributed equitably between countries upon request. governments, ‘Fernandez told a news conference. “Latin American production will be provided by Argentina and Mexico, and this will allow quick and effective access for all countries in the region,” he said after a meeting between President Fernandez and representatives in Buenos Aires of AstraZeneca and mAbxience biotechnology company.
“In Argentina, AstraZeneca has chosen the Masayans laboratory, which will produce the vaccine reagent (…) Mexico will be responsible for packaging the vaccine and completing the production process,” Fernandez said on Wednesday.